Not in first line of treatment
Showing 1 - 25 of >10,000
Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy Trial in Jinan (TQB2450 Injection +
Recruiting
- Limited Stage Small Cell Lung Cancer
- Not Progressed After First-line Chemoradiotherapy
- TQB2450 Injection + Anlotinib Hydrochloride Capsules
-
Jinan, Shandong, ChinaCancer Hospital Affiliated to Shandong First Medical University
Jul 5, 2023
Lung Adenocarcinoma, Cryotherapy Effect Trial in Bordeaux (Cryoablation, Pembrolizumab, Pemetrexed)
Recruiting
- Lung Adenocarcinoma
- Cryotherapy Effect
- Cryoablation
- +3 more
-
Bordeaux, Gironde, FranceInstitut Bergonié
Oct 29, 2021
Urothelial Carcinoma Trial in Irvine, Dallas, Houston (MRx0518, Avelumab 20 mg/mL Intravenous Solution (IV))
Active, not recruiting
- Urothelial Carcinoma
- MRx0518
- Avelumab 20 mg/mL Intravenous Solution (IV)
-
Irvine, California
- +2 more
Jul 5, 2022
Colorectal Cancer Trial in Tai'an (Tas-102(Suyuan) combined with bevacizumab)
Not yet recruiting
- Colorectal Cancer
- Tas-102(Suyuan) combined with bevacizumab
-
Tai'an, Shandong, ChinaThe Second Affiliated Hospital of Shandong First Medical Univers
Oct 14, 2023
Can Digitally Delivered First-line Osteoarthritis Treatment
Recruiting
- Health Services Accessibility
- +2 more
- Digitally delivered first-line treatment for osteoarthritis
- Face-to-face first-line treatment for osteoarthritis
-
Malmö, SwedenJoint Academy
Nov 20, 2023
Tislelizumab Combined With Chemotherapy in First-line Treatment
Active, not recruiting
- Tislelizumab
- +3 more
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 6, 2023
Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)
Not yet recruiting
- Advanced Mucosal Melanoma
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- (no location specified)
Sep 15, 2023
Indolent Non-hodgkin Lymphoma Trial in München (Obinutuzumab, Bendamustine)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
München, Bavaria, GermanyKlinikum der Universität München
Jul 23, 2021
Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
-
Cologne, Germany1st Department of Medicine, Cologne University Hospital
Sep 19, 2023
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line
Recruiting
- Breast Neoplasms
- Inetetamab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Mar 16, 2023
NSCLC Trial in Shanghai (Toripalimab, Cryoablation)
Not yet recruiting
- Non-small Cell Lung Cancer
- Toripalimab
- Cryoablation
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Nov 7, 2023
Colorectal Carcinoma Trial (Fruquintinib?Capecitabine Tablets)
Not yet recruiting
- Colorectal Carcinoma
- Fruquintinib、Capecitabine Tablets
- (no location specified)
Oct 30, 2023
Metastatic Pancreatic Cancer Trial (FOLFIRINOX treatment)
Not yet recruiting
- Metastatic Pancreatic Cancer
- FOLFIRINOX treatment
- (no location specified)
Aug 9, 2023
Metastatic Non Small Cell Lung Cancer Trial in Nicosia (Pembrolizumab)
Unknown status
- Metastatic Non Small Cell Lung Cancer
-
Nicosia, Strovolos, CyprusBank of Cyprus Oncology Centre
Jan 26, 2021
Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))
Recruiting
- Gastrointestinal Neuroendocrine Carcinoma
- Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 1, 2023
First-line Treatment of Non-clear Renal Cell Carcinoma Trial (Fruquintinib combined with Serplulimab)
Not yet recruiting
- First-line Treatment of Non-clear Renal Cell Carcinoma
- Fruquintinib combined with Serplulimab
- (no location specified)
Apr 16, 2023
Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)
Not yet recruiting
- Acral Melanoma
- camrelizumab+apatinib+TMZ
- +2 more
- (no location specified)
Mar 16, 2023